Le Lézard
Classified in: Health
Subjects: SVY, HSP, AVO, DEI

National Alliance for Hispanic Health Cautions FDA on 2022 Report on the Risks and Health Benefits of Non-device Software


WASHINGTON, July 18, 2022 /PRNewswire/ -- "The COVID pandemic has changed the acceptance of mHealth throughout the Nation. There is an urgency in FDA's upcoming Congressionally mandated 2022 Report on the risks and health benefits of non-device software to consider the multitude of mHealth software in the new landscape of health and implications of an ongoing lack of adequate data by race, ethnicity, and gender." said Jane L. Delgado, PhD, MS, President and CEO of the National Alliance for Hispanic Health, the Nation's leading Hispanic health advocacy group. In submitting comments for FDA's proposed 2022 report, the Alliance commended FDA for using in the 2020 report the WHO definition of health, i.e., "a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity," and urges them to take that definition fully into account as they develop the 2022 Report.

The Alliance called for the 2022 FDA report to recognize the patient safety risk as a result of the lack of inclusion of known differences in drug response by race, ethnicity, and gender[i] and the risk of reliance on clinical decision systems (CDS) that lack adequate race, ethnicity, and gender data from clinical trials. Dr. Delgado added, "Over the past 20 years less than half of clinical trials (43%) in the U.S. reported any race or ethnic data."[ii]

About the National Alliance for Hispanic Health (The Alliance)

The Alliance is the nation's foremost science-based source of information and trusted advocate for the health of Hispanics in the United States with a mission to achieve the best health for all. For more information visit us at www.healthyamericas.org


[i] National Alliance for Hispanic Health. Genes, Culture, and Health: Ensuring the Best Health Outcomes for All. Washington, DC: 20015. https://bit.ly/3ckfWfe

[ii] Turner, Brandon, Jecca R. Steinberg, Brannon T. Weeks, Fatima Rodriguez, Mark R. Cullen. "Race/ethnicity reporting and representation in US clinical trials: A cohort study." The Lancet Regional Health ? Americas. Volume 11, July 2022, 100252. https://doi.org/10.1016/j.lana.2022.100252

SOURCE National Alliance for Hispanic Health


These press releases may also interest you

at 16:28
The Rett Syndrome Research Trust (RSRT) is proud to announce its partnership with PMD Solutions, a leading provider of innovative healthcare technologies, in their upcoming biosensor validation study called VIBRANT. PMD Solutions will generously...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31,...

at 16:20
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering. The...

at 16:19
Aflac Incorporated announced today that it will release first quarter 2024 financial results after the market closes on May 1, 2024. At that time, earnings materials, including the quarterly earnings release and financial supplement, will be...

at 16:15
Medpace Holdings, Inc. ("Medpace") today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024. The Company will host a conference call the following morning, Tuesday, April 23, 2024,...



News published on and distributed by: